中度癌症药物在严重的黑素瘤病例中显示出前景,早期试验的回复率为24%。 Modest cancer drug shows promise in tough melanoma cases, with 24% response rate in early trial.

在2025年EMSO大会上,现代方案介绍了其实验性癌症治疗MRNA-4359的早期第1/2阶段试验结果,显示在29名使用MRNA-4359+pemplolizumab治疗后,对前免疫疗法有抗力的高级黑素瘤患者有24%的客观反应率和60%的疾病控制率。 Moderna presented early Phase 1/2 trial results for its experimental cancer therapy mRNA-4359 at the 2025 ESMO Congress, showing a 24% objective response rate and 60% disease control rate in 29 patients with advanced melanoma resistant to prior immunotherapies when treated with mRNA-4359 plus pembrolizumab. 肿瘤显示PD-L1的患者的回复率为67%。 Patients whose tumors expressed PD-L1 had a 67% response rate. 这一疗法引发了有针对性的T细胞反应和新的T细胞受体克隆,没有新的安全关切,反应的中位持续时间尚未达到。 The therapy triggered targeted T cell responses and new T cell receptor clones, with no new safety concerns and a median duration of response not yet reached. mRNA-4359的目标是PD-L1和IDO1,以激活免疫系统,防止癌症。 mRNA-4359 targets PD-L1 and IDO1 to activate the immune system against cancer. 目前正在对黑瘤和非小细胞肺癌的试验中研究治疗方法,这为选择有限的病人提供了潜力。 The treatment is being studied in ongoing trials for melanoma and non-small cell lung cancer, offering potential for patients with limited options.